The compound **1-(1-phenylcyclopentyl)methylamine** is not a widely known or researched molecule. It's likely a synthetic compound that hasn't been extensively studied or characterized.
Here's why we can deduce this:
* **Lack of Common Usage:** There are no known common names or abbreviations for this compound, suggesting it's not a widely used reagent or drug.
* **Unclear Applications:** There's no readily available information about its potential uses in research or medicine.
* **Limited Research:** A quick search on scientific databases like PubMed and SciFinder does not reveal any significant research publications focused on this specific compound.
**Possible Importance:**
However, it's possible that this compound could be of interest for research in the future.
* **Potential as a Ligand:** The molecule contains a phenyl group and an amine group, which are common features of ligands that bind to various receptors or enzymes.
* **Synthetic Building Block:** Its structure might make it a valuable building block for synthesizing other more complex molecules with potential biological activity.
**To understand its importance, we would need:**
* **Detailed information about its synthesis and characterization.**
* **Studies on its biological activity, such as its binding affinity to specific receptors or its effect on cellular processes.**
Without further information, it's impossible to determine the significance of 1-(1-phenylcyclopentyl)methylamine for research.
| ID Source | ID |
|---|---|
| PubMed CID | 205131 |
| CHEMBL ID | 382127 |
| CHEBI ID | 39505 |
| SCHEMBL ID | 294582 |
| Synonym |
|---|
| EN300-24651 |
| BB 0217980 |
| cyclopentanemethylamine, 1-phenyl- |
| brn 2936636 |
| 1-(1-phenylcyclopentyl)methanamine |
| 1-methylamine-1-benzyl-cyclopentane |
| OPREA1_129053 |
| OPREA1_048901 |
| c-(1-phenyl-cyclopentyl)-methylamine |
| chembl382127 , |
| bdbm11555 |
| DB04577 |
| beta-phenethylamine 5 |
| 2BUA |
| (1-phenylcyclopentyl)methanamine |
| CHEBI:39505 , |
| 1-(1-phenylcyclopentyl)methylamine |
| 1-phenylcyclopentanemethylamine |
| 17511-89-6 |
| AKOS000300246 |
| HMS1648D11 |
| 03l0bl8fbi , |
| 4-12-00-02971 (beilstein handbook reference) |
| unii-03l0bl8fbi |
| (1-phenylcyclopentyl)methylamine hydrochloride |
| STK711020 |
| (1-phenylcyclopentyl)methylamine |
| SCHEMBL294582 |
| (1-phenycyclopentyl)methylamine |
| 1-phenyl-cyclopentylmethylamine |
| SJWOFBVBNFLWLP-UHFFFAOYSA-N |
| [(phenylcyclopentyl)methyl]amine |
| cyclopentanemethanamine, 1-phenyl- |
| DTXSID90169933 |
| 1-phenylcyclopentanemethanamine |
| (1-phenylcyclopentyl)methylamine, aldrichcpr |
| mfcd00995874 |
| BS-13780 |
| SY168123 |
| Q27095319 |
| A919161 |
| CS-0117232 |
| ZB1773 |
| AB91940 |
| Z199451530 |
| Class | Description |
|---|---|
| primary aliphatic amine | |
| cyclopentanes | Cyclopentane and its derivatives formed by substitution. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Dipeptidyl peptidase 4 | Sus scrofa (pig) | IC50 (µMol) | 30.7500 | 0.4300 | 1.1400 | 2.5000 | AID1796752; AID261933 |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | IC50 (µMol) | 34.3333 | 0.0001 | 0.4444 | 10.0000 | AID1796752; AID261932; AID262088; AID405516 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| virus receptor activity | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| protease binding | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| aminopeptidase activity | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| serine-type endopeptidase activity | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| signaling receptor binding | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| protein binding | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| serine-type peptidase activity | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| dipeptidyl-peptidase activity | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| identical protein binding | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| protein homodimerization activity | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| chemorepellent activity | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| lysosomal membrane | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| plasma membrane | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| focal adhesion | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| cell surface | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| membrane | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| apical plasma membrane | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| lamellipodium | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| endocytic vesicle | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| lamellipodium membrane | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| membrane raft | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| intercellular canaliculus | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| extracellular exosome | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| plasma membrane | Dipeptidyl peptidase 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1796752 | DPPIV Inhibition Assay from Article 10.1016/j.bmcl.2005.11.103: \\The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors.\\ | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6 | The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. |
| AID261932 | Inhibition of DPP4 by continuous fluorimetric assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6 | The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. |
| AID262088 | Inhibition of DPP4 | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | In silico fragment-based discovery of DPP-IV S1 pocket binders. |
| AID405516 | Binding affinity to DPP4 | 2008 | Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13 | Recent developments in fragment-based drug discovery. |
| AID262089 | Inhibition of DPP4 at 100 uM | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | In silico fragment-based discovery of DPP-IV S1 pocket binders. |
| AID261933 | Inhibition of DPP4 by continuous fluorimetric assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6 | The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||